logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2019
Myovant Sciences Ltd
Data from phase III trial of Relugolix (HERO)
Advanced prostate cancer in Men
Q4 2019
Vascular Biogenics Ltd.
Interim readout from phase III trial of VB-111 (OVAL)
Platinum-resistant ovarian cancer
Q4 2019
Kala Pharmaceuticals, Inc.
Top-line results from additional phase III trial evaluating KPI-121 0.25% (STRIDE 3)
Dry eye disease
Q4 2019
Zosano Pharma Corporation
Filing of NDA for ADAM zolmitriptan
Pain relief by time and recurrence of migraine
Q4 2019
Vascular Biogenics Ltd.
Efficacy interim readout from phase 3 trial of VB-111 (OVAL)
Platinum-resistant ovarian cancer.
Q4 2019
Denali Therapeutics Inc.
Data readout from Phase 1b clinical study of DNL201
Parkinson's disease
Q4 2019
La Jolla Pharmaceutical Co
Filing of NDA for LJPC-0118
Severe malaria
Q4 2019
AVEO Pharmaceuticals, Inc.
More mature interim overall survival outcome from Phase 3 TIVO-3 trial of FOTIVDA
Advanced renal cell cancer in adults
Q4 2019
Insys Therapeutics, Inc.
Data read-out from phase II trial of Cannabidiol oral solution
Prader-Willi syndrome
Q4 2019
Insys Therapeutics, Inc.
Filing of NDA for Epinephrine nasal spray product
Anaphylaxis
Q4 2019
Zosano Pharma Corporation
Filing of NDA for Qtrypta
Migraine
Q4 2019
G1 Therapeutics, Inc.
Preliminary data from phase I/IIa clinical trial of G1T48 as monotherapy
ER+, HER2-breast cancer
Q4 2019
Ascendis Pharma A/S
Top-line results from phase II study of TransCon PTH (PaTH Forward)
Hypoparathyroidism in adults
Q4 2019
ChemoCentryx Inc.
Top-line data from phase III study of Avacopan (ADVOCATE)
ANCA-associated vasculitis
Q4 2019
Arcturus Therapeutics Ltd.
Submission of IND Application for ARCT-810
Ornithine transcarbamylase deficiency
Q4 2019
Denali Therapeutics Inc.
Data readout from phase Ib clinical study of DNL747
Amyotrophic lateral sclerosis
Q4 2019
Denali Therapeutics Inc.
Data readout from phase Ib clinical study of DNL747
Alzheimer's disease
Q4 2019
Forty Seven, Inc.
Report data from Phase 1b trial of 5F9i
Ovarian cancer
Q4 2019
Forty Seven, Inc.
Report data from Phase 1b trial of 5F9n
Colorectal cancer
Q4 2019
Biocryst Pharmaceuticals Inc
Filing of NDA for BCX7353
Hereditary angioedema (HAE) attacks
Q4 2019
Kaleido Biosciences
Data from non-IND clinical study of KB195
Urea cycle disorders, or UCD
Q4 2019
Kaleido Biosciences
Data from non-IND clinical study of KB174
Cirrhosis
Q4 2019
Eidos Therapeutics, Inc.
Data from open-label extension of a phase II clinical trial of AG10
Transthyretin amyloid cardiomyopathy (ATTR-CM)
Q4 2019
Syros Pharmaceuticals
Initial data from phase I trial of SY-1365 as single agent
Ovarian cancer
Q4 2019
Syros Pharmaceuticals
Initial data from phase I trial of SY-1365 in combination with standard-of-care therapies
Ovarian cancer